What You Need to Know About OTC Markets' Stock Promotion Policy (But Were Afraid to Ask)

OTC Markets Group is actively working to establish best practices, enhance market transparency, and address the issue of misleading and manipulative stock promotions.

OTC Markets Group has long been at the forefront of efforts to bring transparency and accountability to the over-the-counter marketplace. One of the most significant — and often misunderstood — aspects of their regulatory framework is the Stock Promotion Policy, which governs how companies and their promoters can communicate with investors.

At its core, the policy requires that any company whose securities are quoted on OTC Markets must disclose all promotional activity, including the identity of the promoter, the compensation paid, and the nature of the campaign. This disclosure requirement is designed to give investors the information they need to make informed decisions, rather than being swayed by hype or misleading claims.

The 'Caveat Emptor' designation — Latin for 'buyer beware' — is one of the most visible tools OTC Markets uses to flag companies that may be engaged in questionable promotional activity. When a company receives this designation, a skull-and-crossbones icon appears next to its ticker symbol on the OTC Markets website, alerting investors to proceed with extreme caution.

What triggers a Caveat Emptor designation? According to OTC Markets Group, the designation can be applied when there is a public interest concern, including spam campaigns, questionable stock promotion, known fraud or other investor protection concerns. The designation can also be applied when a company fails to provide adequate current information to the public.

For legitimate investor relations firms and stock promotion companies, navigating these rules requires careful attention to disclosure requirements. Any compensation received — whether in cash, stock, or other consideration — must be clearly disclosed in all promotional materials. Failure to do so can result in regulatory action by the SEC or FINRA, in addition to the Caveat Emptor designation from OTC Markets.

At OTC Stock Review, we take these disclosure requirements seriously. All of our promotional activities are conducted in full compliance with applicable securities laws and OTC Markets Group policies. We believe that transparency is not just a legal requirement — it is the foundation of a healthy and trustworthy marketplace for small-cap investors.

Investors who are considering investing in OTC-quoted companies should always review the company's disclosure filings, check for any Caveat Emptor designations, and carefully read any promotional materials for compensation disclosures. An informed investor is the best defense against fraud and manipulation in the OTC marketplace.

Please review our full disclaimer for important disclosures regarding compensation and investment risk.